Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021

被引:0
作者
Mateo-Urdiales, Alberto [1 ]
Fabiani, Massimo [1 ]
Mayer, Flavia [2 ]
Sacco, Chiara [1 ,3 ]
Belleudi, Valeria [4 ]
Da Cas, Roberto [2 ]
Fotakis, Emmanouil Alexandros [1 ,3 ]
De Angelis, Luigi [5 ]
Cutillo, Maria [2 ]
Petrone, Daniele [1 ]
Morciano, Cristina [2 ]
Cannone, Andrea [1 ]
Del Manso, Martina [1 ]
Riccardo, Flavia [1 ]
Bella, Antonino [1 ]
Menniti-Ippolito, Franscesca [2 ]
Pezzotti, Patrizio [1 ]
Alegiani, Stefania Spila [2 ]
Massari, Marco [2 ]
机构
[1] Ist Super Sanita, Dept Infect Dis, Rome, Italy
[2] Ist Super Sanita, Natl Ctr Drug Res & Evaluat, Rome, Italy
[3] European Ctr Dis Prevent & Control, European Programme Intervent Epidemiol Training EP, Stockholm, Sweden
[4] ASL Roma 1, Dept Epidemiol, Lazio Reg Hlth Serv, Rome, Italy
[5] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
关键词
HIV; COVID-19; VACCINES; AIDS; MULTICENTER;
D O I
10.1186/s12889-024-19071-y
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background As of 2024, vaccination remains the main mitigation measure against COVID-19, but there are contradictory results on whether people living with HIV (PLWH) are less protected by vaccines than people living without HIV (PLWoH). In this study we compared the risk of SARS-CoV-2 infection and COVID-19 hospitalisation following full vaccination in PLWH and PLWoH.Methods We linked data from the vaccination registry, the COVID-19 surveillance system and from healthcare/pharmacological registries in four Italian regions. We identified PLWH fully vaccinated (14 days post completion of the primary cycle) and matched them at a ratio of 1:4 with PLWoH by week of vaccine administration, age, sex, region of residence and comorbidities. Follow-up started on January 24, 2021, and lasted for a maximum of 234 days. We used the Kaplan-Meier estimator to calculate the cumulative incidence of infection and COVID-19 hospitalisation in both groups, and we compared risks using risk differences and ratios taking PLWoH as the reference group.Results We matched 42,771 PLWH with 171,084 PLWoH. The overall risk of breakthrough infection was similar in both groups with a rate ratio (RR) of 1.10 (95% confidence interval (CI):0.80-1.53). The absolute difference between groups at the end of the study period was 8.28 events per 10,000 person-days in the PLWH group (95%CI:-18.43-40.29). There was a non-significant increase the risk of COVID-19 hospitalisation among PLWH (RR:1.90; 95%CI:0.93-3.32) which corresponds to 6.73 hospitalisations per 10,000 individuals (95%CI: -0.57 to 14.87 per 10,000).Conclusions Our findings suggest PLWH were not at increased risk of breakthrough SARS-CoV-2 infection or COVID-19 hospitalisation following a primary cycle of mRNA vaccination.
引用
收藏
页数:9
相关论文
共 40 条
[21]   Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US [J].
Lang, Raynell ;
Humes, Elizabeth ;
Coburn, Sally B. ;
Horberg, Michael A. ;
Fathi, Lily F. ;
Watson, Eric ;
Jefferson, Celeena R. ;
Park, Lesley S. ;
Gordon, Kirsha S. ;
Akgun, Kathleen M. ;
Justice, Amy C. ;
Napravnik, Sonia ;
Edwards, Jessie K. ;
Browne, Lindsay E. ;
Agil, Deana M. ;
Silverberg, Michael J. ;
Skarbinski, Jacek ;
Leyden, Wendy A. ;
Stewart, Cameron ;
Hogan, Brenna C. ;
Gebo, Kelly A. ;
Marconi, Vincent C. ;
Williams, Carolyn F. ;
Althoff, Keri N. .
JAMA NETWORK OPEN, 2022, 5 (10) :E2236397
[22]   Risk Perception, Preventive Behavior, and Medical Care Avoidance among American Older Adults During the COVID-19 Pandemic [J].
Lu, Peiyi ;
Kong, Dexia ;
Shelley, Mack .
JOURNAL OF AGING AND HEALTH, 2021, 33 (7-8) :577-584
[23]   Behavioral measures to fight COVID-19: An 8-country study of perceived usefulness, adherence and their predictors [J].
Margraf, Jurgen ;
Brailovskaia, Julia ;
Schneider, Silvia .
PLOS ONE, 2020, 15 (12)
[24]   Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis [J].
Marra, Alexandre R. ;
Kobayashi, Takaaki ;
Suzuki, Hiroyuki ;
Alsuhaibani, Mohammed ;
Tofaneto, Bruna Marques ;
Bariani, Luigi Makowski ;
Auler, Mariana de Amorim ;
Salinas, Jorge L. ;
Edmond, Michael B. ;
Doll, Michelle ;
Kutner, Jose Mauro ;
Rebello Pinho, Joao Renato ;
Rizzo, Luiz Vicente ;
Miraglia, Joao Luiz ;
Schweizer, Marin L. .
JOURNAL OF INFECTION, 2022, 84 (03) :297-310
[25]   Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality [J].
Marziano, Valentina ;
Guzzetta, Giorgio ;
Menegale, Francesco ;
Sacco, Chiara ;
Petrone, Daniele ;
Mateo Urdiales, Alberto ;
Del Manso, Martina ;
Bella, Antonino ;
Fabiani, Massimo ;
Vescio, Maria Fenicia ;
Riccardo, Flavia ;
Poletti, Piero ;
Manica, Mattia ;
Zardini, Agnese ;
d'Andrea, Valeria ;
Trentini, Filippo ;
Stefanelli, Paola ;
Rezza, Giovanni ;
Palamara, Anna Teresa ;
Brusaferro, Silvio ;
Ajelli, Marco ;
Pezzotti, Patrizio ;
Merler, Stefano .
INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2023, 17 (08)
[26]   Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study [J].
Massari, Marco ;
Alegiani, Stefania Spila ;
Morciano, Cristina ;
Spuri, Matteo ;
Marchione, Pasquale ;
Felicetti, Patrizia ;
Belleudi, Valeria ;
Poggi, Francesca Romana ;
Lazzeretti, Marco ;
Ercolanoni, Michele ;
Clagnan, Elena ;
Bovo, Emanuela ;
Trifiro, Gianluca ;
Moretti, Ugo ;
Monaco, Giuseppe ;
Leoni, Olivia ;
Da Cas, Roberto ;
Petronzelli, Fiorella ;
Tartaglia, Loriana ;
Mores, Nadia ;
Zanoni, Giovanna ;
Rossi, Paola ;
Samez, Sarah ;
Zappetti, Cristina ;
Marra, Anna Rosa ;
Ippolito, Francesca Menniti .
PLOS MEDICINE, 2022, 19 (07)
[27]   Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 [J].
Mateo-Urdiales, Alberto ;
Alegiani, Stefania Spila ;
Fabiani, Massimo ;
Pezzotti, Patrizio ;
Filia, Antonietta ;
Massari, Marco ;
Riccardo, Flavia ;
Tallon, Marco ;
Proiettis, Valeria ;
Del Manso, Martina ;
Puopolo, Maria ;
Spuri, Matteo ;
Morciano, Cristina ;
D'Ancona, Fortunato ;
Da Cas, Roberto ;
Battilomos, Serena ;
Bella, Antonino ;
Menniti-Ippolito, Francesca .
EUROSURVEILLANCE, 2020, 26 (25) :1-8
[28]  
Ministry of Health, 2021, Indicazioni preliminari sulla somministrazione di dosi addizionali e di dosi. booster nell'ambito della campagna di vaccinazione anti SARS-CoV-2/COVID-19. Prelminar indications about the administration of an additional dose and booster dose in the context of the vaccination campaign anti SARS-CoV-2/COVID-19
[29]   Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥12 years in Italy: A multi-database self-controlled case series study [J].
Morciano, Cristina ;
Alegiani, Stefania Spila ;
Ippolito, Francesca Menniti ;
Belleudi, Valeria ;
Trifiro, Gianluca ;
Zanoni, Giovanna ;
Puccini, Aurora ;
Sapigni, Ester ;
Mores, Nadia ;
Leoni, Olivia ;
Monaco, Giuseppe ;
Clagnan, Elena ;
Zappetti, Cristina ;
Bovo, Emanuela ;
Cutillo, Maria ;
Da Cas, Roberto ;
Massari, Marco .
PLOS ONE, 2024, 19 (01)
[30]  
PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508